Trapidil is as effective as isosorbidedinitrate for treating stable angina pectoris - A multinational, multicenter, double-blind, randomized study

Clinical Research in Cardiology

Volumn 95, Issue 4, 2006, Pages 217-223

  Meinertz, T ^a   Lehmacher, W ^b  

^a UNIVERSITY OF HAMBURG   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Chronic angina pectoris; ISDN; Trapidil

Indexed keywords

ANTIANGINA PECTORIS AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; GLYCERYL TRINITRATE; ISOSORBIDE DINITRATE; LOW DENSITY LIPOPROTEIN; NITRATE; TRAPIDIL; VASODILATOR AGENT;

ADULT; AGED; ARTICLE; ASTHENIA; BICYCLE ERGOMETER; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; DYSPEPSIA; ECG ABNORMALITY; EXERCISE TEST; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; RANDOMIZED CONTROLLED TRIAL; STABLE ANGINA PECTORIS; STATISTICAL SIGNIFICANCE; TACHYCARDIA; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; ANGINA PECTORIS; BLOOD PRESSURE; CHRONIC DISEASE; ENDURANCE; EXERCISE TOLERANCE; HEART RATE; MIDDLE AGED; PATHOPHYSIOLOGY;

ADULT; AGED; ANGINA PECTORIS; BLOOD PRESSURE; CHRONIC DISEASE; DOUBLE-BLIND METHOD; EXERCISE TEST; EXERCISE TOLERANCE; FEMALE; HEART RATE; HUMANS; ISOSORBIDE DINITRATE; MALE; MIDDLE AGED; PHYSICAL ENDURANCE; TRAPIDIL; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 33645394161     PISSN: 18610684     EISSN: 18610692     Source Type: Journal    
DOI: 10.1007/s00392-006-0367-x     Document Type: Article

References (42)

1. Abrams J (1995) The role of nitrates in coronary heart disease. Arch Intern Med 155:357-364
2. ACC/AHA/ACP-ASIM (1999) Practice guidelines for the management of patients with chronic stable angina. J Am Coll Cardiol 33:2092-2197
3. Dietz R, Rauch B (2003) Leitlinie zur Diagnose und Behandlung der chronisch koronaren Herzerkrankung der Deutschen Gesellschaft für Kardiologie - Herz und Kreislaufforschung (DGK). Z Kardiol 92:501-521
4. Asirvatham S, Sebastian C, Thadani U (1998) Choosing the most appropriate treatment for stable angina. Safety conditions. Drug Saf 19(1):23-44
5. Olsson G, Allgén J (1991) Is there an optimal prophylactic nitrate therapy? Eur Heart J 12(Suppl A):21-23
6. Cleophas TJ, Niemeyer MC, van der Wall EE et al on behalf of the 5-ISMN headache study group (1996) Angiology 47(7):679-685
7. Parker JO, Baird MG (1994) Efficacy of eccentric dosing with sustained-release isosorbide dinitrate in patients with angina pectoris. Can J Card 10:909-912
8. Caramori PR, Zago AJ (2000) Endothelial dysfunction and coronary artery disease. Arg Bras Cardiol 75:163-182
9. Gori T, Mak SS, Kelly S, Parker JD (2001) Evidence supporting abnormalities in nitric oxide synthase function induced by nitroglycerin in humans. J Am Coll Cardiol 38:1102-1105
10. Münzel T, Sayegh H, Freeman BA, Tarpey MM, Harrison DG (1995) Evidence for enhanced vascular superoxide anion production in nitrate tolerance J Clin Invest 95:187-195
11. Nakamura Y (1999) Long-term nitrate use may be deleterious in ischemic heart disease: A study using the databases from two large-scale post-infarction studies. Am Heart J 138;3(1):577-585
12. Sichelschmidt OJ, Hahnefeld C, Hohlfeld Th et al (2003) Trapidil protects ischemic hearts from reperfusion injury by stimulating PKAII activity. Cardiovascular Research (58):602-610
13. Schrör K, Zwaka P, Tannhäuser R (1998) Cardioprotective actions of Trapidil in myocardial ischemia involve inhibition of the activation of NfKb. Exp Biol, p 198
14. Boenisch D, Weber AA, Wittpoth M et al (1998) Antimitogenic effects of trapidil in coronary artery smooth muscle cells by direct activation of protein kinase. A Mol Pharmacol 54:241-248
15. Wittpoth M et al (1997) Trapidil inhibits PDGF-BB and LPS induced translocation of NFκB in vascular smooth muscle cells. Naunyn Schmied Arch Pharmacol 355/4 Suppl
16. Schroer K, Bönisch D (1997) Trapidil inhibits RAF-1 kinase in vascular smooth muscle cells via activation of protein kinase A (PKA). Circulation 96:I-1-I-901
17. Raubach KH, Vlahov V, Wolter K et al (1997) Double-blind randomized multicentre study on the efficacy of trapidil vs. isosorbide dinitrate in stable angina pectoris. Clin Cardiol 20:483-488
18. Aßmann I, Lehrl I, Lehrl S et al (1996) Behandlung der körperlichen, emotionalen und kognitiven Belastbarkeit bei Patienten mit koronarer Herzkrankheit unter Trapidil im Vergleich zu Nifedipin. Arzneimittelforschung 46/9:868-874
19. Fihn SD, Williams SV, Daley J et al (2001) Guidelines for the management of patients with chronic stable angina: Treatment. Ann Int Med 135:616-632
20. ESC (1993) Working Group on Exercise Physiology, Physiopathology and Electrocardiography. Guidelines for cardiac exercise testing. Eur Heart J 14:969-988
21. Shapiro W (1992) Comparative efficacy of bepridil vs. placebo in angina pectoris: Treatment and withdrawal studies. Am J Cardiol 69:43D-49D
22. Glasser SP, Friedman R, Talibi T et al (1994) Safety and compatibility of betaxolol hydrochloride combined with diltiazem or nifedipine therapy in stable angina pectoris. Am J Cardiol 73(4):213-218
23. Thadani U, Bittar N (1992) Effects of 8:00 a.m. and 20:00 p.m. doses of isosorbide-5-mononitrate during twice-daily therapy in stable angina pectoris. Am J Cardiol 70:286-292
24. Bakx ALM, van der Wall EE, Braun S et al (1995) Effects of the new calcium antagonist mibefradil (Ro 40-5967) on exercise duration in patients with chronic stable angina pectoris. A multicentre, placebo-controlled study. Am Heart J 130:748-757
25. Fox KM, Mukahy D, Findlay I et al (1996) on behalf of the TIBET Study Group. The Total Ischemic Burden European Trial (TIBET). Eur Heart J 17:96-103
26. Alpert JS, Bakx LM, Braun S et al (1997) Antianginal and anti-ischemic effects of mibefradil in the treatment of patients with chronic stable angina pectoris. Am J Cardiol 80(4B):20C-26C
27. Walker JM, Curry PVL, Bailey AS et al (1996) A comparison of nifedipine once daily (Adalat LA), isosorbide mononitrate once daily, and isosorbide dinitrate twice daily in patients with chronic stable angina. Internat J Cardiol 53:117-126
28. Fox KM, Jespersen CM, Ferrari R et al (1997) How European cardiologists perceive the role of calcium antagonists in the treatment of stable angina. Eur Heart J 18/Suppl A:A113
29. Weiss RJ, Hicks D, Bittar N et al (1993) and the Sustained-Release Diltiazem Study Group. A double-blind placebo-controlled trial of sustained-release diltiazem in patients with angina. Clinical Therapeutics 15:1069-1075
30. Eteiba H, Hutton, I Foale RA et al (1991) Acute and chronic effects of once-daily isosorbide-5-mononitrate on exercise capacity of patients with angina pectoris treated with beta-blocking agent. Br J Clin Pharmacol 45:185-188
31. Davies GJ, Kobrin I, Caspi A et al (1997) Long-term anti-anginal and anti-ischemic effects of mibefradil, the novel T-type calcium channel blocker: A multicentre, double-blind, placebo-controlled, randomized comparison with sustained-release diltiazem. Am Heart J 134:220-228
32. Kohl O, Grebe M, Hölschemann H et al (2004) Fortbestehende Angina pectoris trotz erfolgreicher Myokardrevaskularisation. Z Kardiol 93:63-68
33. Lutter G, Frey M, Saurbier B et al (1998) Treatment option for patients with otherwise intractable angina pectoris: Transmyocardial laser revascularisation. Z Kardiol 87(Suppl 2): s199-s202
34. Lauer B, Schuler G (2000) Myokardiale Laserrevascularisation bei therapierefraktäerer Angina pectoris. Z Kardiol 89:810-814
35. Ries MW, Rupprecht HJ, Dudsjak H et al (1999) Freisetzung von Troponin T im Rahmen der PTCA bei Patienten mit instabiler und stabiler Angina pectoris. Z Kardiol 88:914-921
36. Klepzig H, Krobot K, Flettner R et al (1999) Determinanten der Behandlungskosten instabiler Angina pectoris. Z Kardiol 88:261-269
37. Werner D, Hui JCK, Kropp J et al (1998) Pneumatische externe Gegenpulsation- Therapieoption bei Angina pectoris. Z Kardiol 87(Suppl 2):s193-s198
38. Lauer B, Stahl F, Bratanow S et al (2000) Perkutane myokardiale Laserrevaskularisation (PMR), ein neues Therapieverfahren für Patienten mit therapierefraktärer Angina pectoris. Z Kardiol 89(Suppl 7):31-36
39. Schoebel FC, Peters AJ, Schannwell CM et al (1998) Detection of anti-ischemic therapeutic effectiveness in patients with refractory angina pectoris and end-stage coronary artery disease- Long-term intermittent urokinase therapy. Z Kardiol 87(Suppl 2): s188-s192
40. +-Kanalblockers Tedisamil auf Hämodynamik, Myokardischämie und neurohumorales System bei Patienten mit stabiler Angina pectoris. Ein Vergleich mit dem β-Blocker Atenolol. Z Kardiol 88:838-849
41. Gulba DC, Eichstädt H, Engberding R et al (2000) Empfehlungen des International Cardiology Forum (ICF) 1998 zur Revisison der bestehenden Richtlinien zur Diagnostik und Therapie der instabline Angina pectoris und des nicht-transmuralen Myokardinfarktes. Z Kardiol 89:706-721
42. Baller D, Gleichmann U, Notohamiprodjo G et al (1998) Improvement of coronary vasodilator capacity by lipid-lowering therapy in patients with angina pectoris, reduced cornary reserve and moderate LDL-hypercholesterolemia. Z Kardiol 87(Suppl 2): s136-s144